FDA OKs Pembrolizumab for Adjuvant Treatment of NSCLC FDA OKs Pembrolizumab for Adjuvant Treatment of NSCLC

The agency expanded the indication for pembrolizumab to the adjuvant setting for patients with stage IB-IIIA NSCLC following surgery and platinum-based chemo.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news